Document Detail

Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics.
MedLine Citation:
PMID:  21091097     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Some patients with rheumatoid arthritis (RA) who receive injectable biologics experience injection-site burning and stinging (ISBS); however, the prevalence of ISBS in the general RA population is unknown and may impact preference for an injectable biologic. This study assessed the prevalence of ISBS and associated comorbidities in patients with RA who receive injectable biologics.
RESEARCH DESIGN AND METHODS: The physician and patient survey consisted of a retrospective chart review and a prospective assessment. In the former, each participating US rheumatologist reviewed the medical records of five randomly selected RA patients receiving an injectable biologic. In the prospective assessment, each rheumatologist was asked to report data based on interviews with up to 50 RA patients currently treated with an injectable biologic, who were asked whether they had ISBS during or after their most recent injection.
RESULTS: Data were analyzed for 504 patients in the retrospective chart review and 3326 patients in the prospective assessment; data were provided by 101 physicians. The overall prevalence of ISBS was 17% and 58% in the retrospective chart review and prospective analyses, respectively. Out of the 1939 prospectively assessed patients who experienced at least some ISBS, 429 (22%) rated the level of ISBS as moderate to severe (13% of total). Increased risk of ISBS was associated with female gender, fibromyalgia, depression, and more severe RA.
CONCLUSIONS: The prevalence of ISBS is likely underestimated in many rheumatology practices. Specifically asking about it may identify patients who experience this side effect, provide a more accurate understanding of how significantly it affects them, and provide an opportunity for intervention in light of their preferences.
Jeffrey R Curtis; Coburn Hobar; Kevin Hansbrough
Related Documents :
19552717 - The influence of treatment on quality of life in systemic lupus erythematosus patients.
1467197 - Nausea and vomiting and cancer patients' quality of life: a discussion of professor sel...
19233587 - Health care provider attitudes toward patients with acute vaso-occlusive crisis due to ...
23016807 - Updates in the american heart association guidelines for cardiopulmonary resuscitation ...
8158667 - Assisting low-vision patients in japan.
23315167 - Clinical experience with fetal hemoglobin induction therapy in patients with β-thalasse...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-22
Journal Detail:
Title:  Current medical research and opinion     Volume:  27     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-17     Completed Date:  2011-04-01     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  71-8     Citation Subset:  IM    
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL 35294-7201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / administration & dosage*
Arthritis, Rheumatoid / drug therapy*,  epidemiology
Biological Agents / administration & dosage*
Injections / adverse effects
Middle Aged
Pain / epidemiology,  etiology*
Physicians / statistics & numerical data
Professional Competence / statistics & numerical data
Retrospective Studies
Syringes / adverse effects*
Grant Support
Reg. No./Substance:
0/Antirheumatic Agents; 0/Biological Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE...
Next Document:  Humanistic and economic impacts of hepatitis C infection in the United States.